{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T23:06:46Z","timestamp":1770160006192,"version":"3.49.0"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grant Agency of the Ministry of the Education, Science, Research, and Sport of the Slovak Republic","award":["VEGA 1\/0617\/22"],"award-info":[{"award-number":["VEGA 1\/0617\/22"]}]},{"name":"Internal Scientific Grant System of Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice","award":["VVGS-2023-2747"],"award-info":[{"award-number":["VVGS-2023-2747"]}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["VV-MVP-24-0135"],"award-info":[{"award-number":["VV-MVP-24-0135"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>SLAMF7, also known as CD319, a SLAM (signaling lymphocytic activation molecule) family receptor, is relatively weakly expressed on chronic lymphocytic leukemia (CLL) B cells. This study evaluated the ability of elotuzumab (E), an anti-SLAMF7\/CD319 antibody, to induce antibody-dependent cellular cytotoxicity (ADCC) against CLL cell lines (MEC-1, MEC-2, CI, HG-3, PGA-1, WA-OSEL). ADCC was assessed by flow cytometry using E (100 \u03bcg\/mL), rituximab (R, 100 \u03bcg\/mL), and their combination (E + R). CLL lines served as targets (T), while peripheral blood mononuclear cells (PBMCs) or NK cells from healthy donors served as effectors (E) at an 8:1 E:T ratio for 4 h. With PBMCs, E-induced ADCC ranged from 1.3 \u00b1 1.2% (PGA-1) to 14.6 \u00b1 8.1% (MEC-1); R-induced ADCC ranged from 9.2 \u00b1 4.6% (PGA-1) to 16.6 \u00b1 9.4% (WA-OSEL). With NK cells, E-induced ADCC ranged from 1.8 \u00b1 3.7% (PGA-1) to 27.3 \u00b1 4.7% (MEC-1); R-induced ADCC ranged from 5.1 \u00b1 4.3% (PGA-1) to 27.5 \u00b1 13.6% (CI). E outperformed R in MEC-1, while R was superior elsewhere. Cell lines with higher SLAMF7\/CD319 expression displayed increased sensitivity to E. Cell lines with del17p showed higher SLAMF7\/CD319 expression. The combination of E + R showed no significant synergy over monotherapies. In conclusion, elotuzumab induced significant ADCC in CLL cells, warranting further therapeutic evaluation.<\/jats:p>","DOI":"10.3390\/molecules31030531","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:03:29Z","timestamp":1770113009000},"page":"531","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Anti-SLAMF7 Antibody, Elotuzumab, Induces Antibody-Dependent Cellular Cytotoxicity Against CLL Cell Lines"],"prefix":"10.3390","volume":"31","author":[{"given":"Dominik","family":"K\u013eoc","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice, Trieda SNP 1, 04011 Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Dubikov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice, Trieda SNP 1, 04011 Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"\u017dil\u00e1kov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice, Trieda SNP 1, 04011 Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1n","family":"Sykora","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncohaematology, Faculty of Medicine, Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice and Louis Pasteur University Hospital Ko\u0161ice, Trieda SNP 1, 04011 Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-1629","authenticated-orcid":false,"given":"Michaela","family":"\u0160ulikov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice, Trieda SNP 1, 04011 Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3829-0336","authenticated-orcid":false,"given":"Slavom\u00edr","family":"Kurhajec","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Pharmacognosy, and Botany, University of Veterinary Medicine and Pharmacy, Komensk\u00e9ho 73, 04181 Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5943-9451","authenticated-orcid":false,"given":"J\u00e1n","family":"Sabo","sequence":"additional","affiliation":[{"name":"Department of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice, Trieda SNP 1, 04011 Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6335-0399","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Guman","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncohaematology, Faculty of Medicine, Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice and Louis Pasteur University Hospital Ko\u0161ice, Trieda SNP 1, 04011 Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2243-5286","authenticated-orcid":false,"given":"Marek","family":"\u0160ari\u0161sk\u00fd","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice, Trieda SNP 1, 04011 Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"IwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/ajcp\/108.4.378","article-title":"Improvement of the Chronic Lymphocytic Leukemia Scoring System With the Monoclonal Antibody SN8(CD79b)","volume":"108","author":"Moreau","year":"1997","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible Diagnosis of Chronic Lymphocytic Leukemia by Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_5","unstructured":"(2025, December 05). SEER*Explorer Application, Available online: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on#resultsRegion0."},{"key":"ref_6","first-page":"7","article-title":"Cancer Statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline Interim Update on New Targeted Therapies in the First Line and at Relapse of Chronic Lymphocytic Leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM Family Receptors and SAP Adaptors in Immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"K\u013eoc, D., Kurhajec, S., Huniadi, M., S\u00fdkora, J., Guman, T., and \u0160ari\u0161sk\u00fd, M. (2024). SLAM Family Receptors in B Cell Chronic Lymphoproliferative Disorders. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25074014"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1080\/10428194.2016.1251593","article-title":"Altered Expression Pattern of SLAM Family Receptors on Pathological B Cells of Patients with Chronic Lymphocytic Leukemia","volume":"58","author":"Coma","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"26346","DOI":"10.18632\/oncotarget.8378","article-title":"A Combination of an Anti-SLAMF6 Antibody and Ibrutinib Efficiently Abrogates Expansion of Chronic Lymphocytic Leukemia Cells","volume":"7","author":"Yigit","year":"2016","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.15393","article-title":"SLAMF7 (CD319\/CS1) Is Expressed in Plasmablastic Lymphoma and Is a Potential Diagnostic Marker and Therapeutic Target","volume":"185","author":"Shi","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00262-022-03177-6","article-title":"Elotuzumab, a Potential Therapeutic Humanized Anti-SLAMF7 Monoclonal Antibody, Enhances Natural Killer Cell-Mediated Killing of Primary Effusion Lymphoma Cells","volume":"71","author":"Panaampon","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.imlet.2010.09.021","article-title":"Expression of SLAM (CD150) Cell-Surface Receptors on Human B-Cell Subsets: From pro-B to Plasma Cells","volume":"134","author":"Sintes","year":"2011","journal-title":"Immunol. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1172\/JCI83013","article-title":"SLAMF1 Regulation of Chemotaxis and Autophagy Determines CLL Patient Response","volume":"126","author":"Bologna","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/10428199409056297","article-title":"A Pilot Clinical Trial of Two Murine Monoclonal Antibodies Fixing Human Complement in Patients with Chronic Lymphatic Leukaemia","volume":"13","author":"Greenaway","year":"1994","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/onc.2016.238","article-title":"CD84 Mediates CLL-Microenvironment Interactions","volume":"36","author":"Marom","year":"2017","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2007.06569.x","article-title":"The Lymphoid Cell Surface Receptor NTB-A: A Novel Monoclonal Antibody Target for Leukaemia and Lymphoma Therapeutics","volume":"137","author":"Korver","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-18-0664","article-title":"SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer","volume":"7","author":"Yigit","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(98)00154-4","article-title":"MEC1 and MEC2: Two New Cell Lines Derived from B-Chronic Lymphocytic Leukaemia in Prolymphocytoid Transformation","volume":"23","author":"Stacchini","year":"1999","journal-title":"Leuk. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3109\/10428194.2013.764418","article-title":"Molecular Characterization of Neoplastic and Normal \u201cSister\u201d Lymphoblastoid B-Cell Lines from Chronic Lymphocytic Leukemia","volume":"54","author":"Hellqvist","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/onc.2013.31","article-title":"CD84 Is a Survival Receptor for CLL Cells","volume":"33","author":"Marom","year":"2014","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.1073\/pnas.95.23.13765","article-title":"Inactivating Mutations in an SH2 Domain-Encoding Gene in X-Linked Lymphoproliferative Syndrome","volume":"95","author":"Nichols","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ijc.10986","article-title":"Expression of SH2D1A in Five Classical Hodgkin\u2019s Disease-Derived Cell Lines","volume":"104","author":"Kis","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2004-04-1273","article-title":"The Adaptor Protein SH2D1A Regulates Signaling through CD150 (SLAM) in B Cells","volume":"104","author":"Mikhalap","year":"2004","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3324\/haematol.10864","article-title":"Expression of Two Markers of Germinal Center T Cells (SAP and PD-1) in Angioimmunoblastic T-Cell Lymphoma","volume":"92","author":"Roncador","year":"2007","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19772","DOI":"10.1038\/srep19772","article-title":"A Novel Method for Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Flowcytometry Using Cryopreserved Human Peripheral Blood Mononuclear Cells","volume":"6","author":"Yamashita","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Campbell, K.S., Cohen, A.D., and Pazina, T. (2018). Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02551"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab Directly Enhances NK Cell Cytotoxicity against Myeloma via CS1 Ligation: Evidence for Augmented NK Cell Function Complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/2326-6066.CIR-18-0579","article-title":"Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma","volume":"7","author":"Pazina","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1429879","DOI":"10.1155\/2024\/1429879","article-title":"Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes","volume":"2024","author":"Wang","year":"2024","journal-title":"J. Immunol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1158\/1078-0432.CCR-08-1536","article-title":"An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy","volume":"15","author":"Mishima","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","article-title":"Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity","volume":"12","author":"Hol","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 Levels Determine the in Vitro Susceptibility to Rituximab and Complement of B-Cell Chronic Lymphocytic Leukemia: Further Regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00277-012-1407-4","article-title":"Association of CD20 Levels with Clinicopathological Parameters and Its Prognostic Significance for Patients with DLBCL","volume":"91","author":"Suzuki","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1182\/blood-2008-09-177469","article-title":"Diffuse Large B-Cell Lymphoma: Reduced CD20 Expression Is Associated with an Inferior Survival","volume":"113","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab Enhances Natural Killer Cell Activation and Myeloma Cell Killing through Interleukin-2 and TNF-\u03b1 Pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.4049\/jimmunol.181.4.2916","article-title":"Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi Cells Is Promoted by NK Cells and Inhibited by Monocytes Due to Shaving","volume":"181","author":"Beum","year":"2008","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow Antibody Panels for Standardized N-Dimensional Flow Cytometric Immunophenotyping of Normal, Reactive and Malignant Leukocytes","volume":"26","author":"Lhermitte","year":"2012","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2478\/afpuc-2022-0007","article-title":"Optimisation of Flow Cytometric Detection of Intracellular SLAMF Receptor-Associated Adaptor Proteins SAP and EAT-2","volume":"69","author":"Huniadi","year":"2022","journal-title":"Eur. Pharm. J."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/3\/531\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:04:16Z","timestamp":1770113056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/3\/531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["molecules31030531"],"URL":"https:\/\/doi.org\/10.3390\/molecules31030531","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}